Transcranial magnetic stimulation
( DrugBank: - / KEGG DRUG: - )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 2 |
| 13 | Multiple sclerosis/Neuromyelitis optica | 5 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 77 | Growth hormone secreting pituitary adenoma | 1 |
6. Parkinson disease
Clinical trials : 2,586 / Drugs : 1,871 - (DrugBank : 354) / Drug target genes : 188 - Drug target pathways : 205
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,685 / Drugs : 1,932 - (DrugBank : 355) / Drug target genes : 263 - Drug target pathways : 237
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
77. Growth hormone secreting pituitary adenoma
Clinical trials : 351 / Drugs : 241 - (DrugBank : 28) / Drug target genes : 26 - Drug target pathways : 87
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|